Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS -1.33%61 PB Ratio is 1.96 as of Jul. 14, 2026, which is 74% below its 10-year median of 7.46. GuruFocus rates NSE:REMUS with a GF Score™ of 61/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 110 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 68.18% on this metric.
The historical rank and industry rank for Remus Pharmaceuticals's PB Ratio or its related term are showing as below:
NSE:REMUS'
s PB Ratio Range Over the Past 10 Years
Min: 1.69 Med: 7.46 Max: 175.28
Current: 1.96
During the past 7 years, Remus Pharmaceuticals's highest PB Ratio was 175.28. The lowest was 1.69. And the median was 7.46.
NSE:REMUS's PB Ratio is ranked worse than 68.18% of 110
companies
in the Medical Distribution industry
Industry Median: 0.965
vs NSE:REMUS: 1.96
During the past 12 months, Remus Pharmaceuticals's average Book Value Per Share Growth Rate was 71.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 184.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 196.20% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Remus Pharmaceuticals was 272.70% per year. The lowest was 111.40% per year. And the median was 212.80% per year.
Back to Basics: PB Ratio
Remus Pharmaceuticals (NSE:REMUS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Remus Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Remus Pharmaceuticals (NSE:REMUS) has a PB Ratio of 1.96 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Remus Pharmaceuticals and its competitors. This is 74% below median its historical median of 7.46. Over the past decade, Remus Pharmaceuticals' PB Ratio has ranged from 1.69 to 175.28. According to the industry distribution chart, Remus Pharmaceuticals ranks #75 out of 110 companies in the Medical Distribution industry, placing it in the top 68.2%.
Is Remus Pharmaceuticals' PB Ratio too high?
Remus Pharmaceuticals' current PB Ratio of 1.96 is 74% below median its 10-year median of 7.46. Over the past 10 years, this metric has ranged from a low of 1.69 to a high of 175.28. The Medical Distribution industry median PB Ratio is 0.97. Remus Pharmaceuticals' value of 1.96 is 103.1% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #75 out of 110 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' PB Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #75 out of 110 companies for PB Ratio. This places Remus Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 0.97. Remus Pharmaceuticals' value of 1.96 is 103.1% above this benchmark. Historically, Remus Pharmaceuticals' own PB Ratio has ranged from 1.69 to 175.28 over the past decade. While the company's 10-year median is 7.46 vs. the industry median of 0.97, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 0.97, based on 110 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current PB Ratio of 1.96 is 103.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median PB Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current PB Ratio is 1.96, which is 74% below median its own 10-year median of 7.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹730.10 — trading 64.8% below its estimated fair value. The current PB Ratio is 1.96, which is 74% below median its 10-year median of 7.46 and 103.1% above the Medical Distribution industry median of 0.97. Remus Pharmaceuticals' overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current PB Ratio is 1.96 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹730.10 is trading 64.8% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
PB Ratio: 1.96 (74% below median its 10-year median of 7.46)
GF Value™: ₹2,071.36 vs. price of ₹730.10 (64.8% below fair value)
Industry Position: 103.1% above the Medical Distribution median (#75 of 110)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
61GF Score
Get the complete analysis for NSE:REMUS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
